TScan Therapeutics laid off roughly 30% of its workforce and stopped its Phase 1 solid‑tumor T‑cell receptor (TCR) trial to concentrate resources on blood‑cancer programs. The company cited a strategic refocus and pipeline reassessment as drivers of the change. The move ends an early solid‑tumor effort and raises questions about the clinical and commercial viability of certain engineered TCR approaches in solid malignancies. For investors and partners, the cut signals heightened caution across smaller cell‑therapy developers when facing complex manufacturing, regulatory, and efficacy hurdles. Industry watchers will track whether TScan seeks partnerships, assets sales, or additional financing as it reshapes its development plan.